| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,242,049 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
| Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
11 |
21 |
41 |
87 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barbari Sharon Surrey |
EVP, Finance & CFO |
• – – |
2009-11-16 |
4 |
OE |
$3.37 |
$6,740 |
D/D |
2,000 |
14,127 |
|
- |
|
| Sabry James H |
Director |
– • – |
2009-11-16 |
4 |
S |
$3.38 |
$225,832 |
D/D |
(66,000) |
0 |
|
- |
|
| Sabry James H |
Director |
– • – |
2009-11-16 |
4 |
OE |
$1.20 |
$79,200 |
D/D |
66,000 |
65,900 |
|
- |
|
| Sabry James H |
Director |
– • – |
2009-11-13 |
4 |
S |
$3.34 |
$221,617 |
D/D |
(66,200) |
0 |
|
- |
|
| Sabry James H |
Director |
– • – |
2009-11-13 |
4 |
OE |
$0.58 |
$20,845 |
D/D |
35,940 |
35,940 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-11-10 |
4 |
AS |
$3.24 |
$1,620 |
D/D |
(500) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-11-10 |
4 |
OE |
$1.20 |
$600 |
D/D |
500 |
22,960 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-10-22 |
4 |
AS |
$4.77 |
$2,385 |
D/D |
(500) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-10-22 |
4 |
OE |
$1.20 |
$600 |
D/D |
500 |
22,960 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-10-08 |
4 |
AS |
$4.85 |
$2,425 |
D/D |
(500) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-10-08 |
4 |
OE |
$1.20 |
$600 |
D/D |
500 |
22,960 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-10-01 |
4 |
AS |
$5.17 |
$38,975 |
D/D |
(7,500) |
42,000 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-09-28 |
4 |
AS |
$5.50 |
$13,750 |
D/D |
(2,500) |
49,500 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-09-24 |
4 |
AS |
$4.62 |
$2,310 |
D/D |
(500) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-09-24 |
4 |
OE |
$1.20 |
$600 |
D/D |
500 |
22,960 |
|
- |
|
| Morgans David J Jr |
EVP-Preclinical R&D |
• – – |
2009-09-21 |
4 |
AS |
$4.69 |
$36,230 |
D/D |
(7,500) |
52,000 |
|
- |
|
| Sabry James H |
Director |
– • – |
2009-09-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
30,260 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-09-10 |
4 |
AS |
$3.21 |
$1,605 |
D/D |
(500) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-09-10 |
4 |
OE |
$1.20 |
$600 |
D/D |
500 |
22,960 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-08-04 |
4 |
AS |
$3.00 |
$3,000 |
D/D |
(1,000) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-08-04 |
4 |
OE |
$1.20 |
$1,200 |
D/D |
1,000 |
23,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-07-22 |
4 |
AS |
$2.83 |
$2,830 |
D/D |
(1,000) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-07-22 |
4 |
OE |
$1.20 |
$1,200 |
D/D |
1,000 |
23,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-07-08 |
4 |
AS |
$2.72 |
$2,720 |
D/D |
(1,000) |
22,460 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2009-07-08 |
4 |
OE |
$1.20 |
$1,200 |
D/D |
1,000 |
23,460 |
|
- |
|
1115 Records found
|
|
Page 33 of 45 |
|
|
0.38 (0.71%) 
